Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 94Carcinoma, Non-Small-Cell Lung 84Prostatic Neoplasms 74Multiple Myeloma 74Neoplasms 46Melanoma 41Lymphoma 41Leukemia, Myeloid, Acute 41Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 34Lung Neoplasms 34Lymphoma, Non-Hodgkin 33Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 28Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 20Lymphoma, Follicular 20Fallopian Tube Neoplasms 20Carcinoma, Renal Cell 20Sarcoma 19Urinary Bladder Neoplasms 18Recurrence 18Head and Neck Neoplasms 18Small Cell Lung Carcinoma 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × 90 days × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡